A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Phase of Trial: Phase II
Latest Information Update: 13 Mar 2015
At a glance
- Drugs TD 9855 (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Proof of concept; Therapeutic Use
- Sponsors Theravance Biopharma
- 04 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 Nov 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 25 Jul 2013 Theravance expects to report results from this trial in second half of 2013.